½ÃÀ庸°í¼­
»óǰÄÚµå
1813448

Àüµµ¼º ½Å°æ ¸ð´ÏÅ͸µ ½ÃÀå ¿¹Ãø(-2032³â) : Á¦Ç° À¯Çü, ¼Ò½º À¯Çü, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ, Áö¿ªº° ¼¼°è ºÐ¼®

Conductive Neuromonitoring Market Forecasts to 2032 - Global Analysis By Product Type, Source Type, Application, End User and By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Stratistics Market Research Consulting | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200+ Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Stratistics MRC¿¡ µû¸£¸é ¼¼°èÀÇ Àüµµ¼º ½Å°æ ¸ð´ÏÅ͸µ ½ÃÀåÀº 2025³â¿¡ 3¾ï 7,480¸¸ ´Þ·¯¸¦ Â÷ÁöÇϰí, ¿¹Ãø ±â°£ µ¿¾È CAGRÀº 7.1%¸¦ ³ªÅ¸³» 2032³â¿¡´Â 6¾ï 580¸¸ ´Þ·¯¿¡ À̸¦ Àü¸ÁÀÔ´Ï´Ù.

Àüµµ¼º ½Å°æ ¸ð´ÏÅ͸µÀº ÁßÃß ½Å°æ°è¿Í ¸»ÃÊ ½Å°æ°è¸¦ °¡·Î Áö¸£´Â Àü±â Àüµµ¸¦ ÃøÁ¤ÇÏ´Â Àü±â »ý¸® ±â¼úÀ» »ç¿ëÇÏ¿© ½Å°æ °æ·ÎÀÇ ¹«°á¼ºÀ» ½Ç½Ã°£À¸·Î Æò°¡ÇÏ´Â °ÍÀÔ´Ï´Ù. ÀϹÝÀûÀ¸·Î ¼ö¼ú ½Ã¿¡ »ç¿ëµÇ¸ç ü¼º°¨°¢À¯¹ßÀüÀ§(SSEP), ¿îµ¿À¯¹ßÀüÀ§(MEP), ±ÙÀüµµ(EMG) µîÀÇ ¸ð´Þ¸®Æ¼¸¦ ÀÌ¿ëÇÏ¿© ÀáÀçÀûÀÎ ½Å°æÀå¾Ö¸¦ °ËÃâÇÕ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀº ±â´É »óÅ¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ Çǵå¹éÀ» Á¦°øÇÔÀ¸·Î½á ÀÓ»óÀǰ¡ ¼ö¼ú Áß ½Å°æ ¼Õ»óÀ» È®ÀÎÇÏ°í ¿¹¹æÇÒ ¼ö ÀÖ°Ô ÇÏ¿© ȯÀÚÀÇ ¾ÈÀü¼º°ú ¼ö¼ú °á°ú¸¦ Çâ»ó½Ãŵ´Ï´Ù.

½Å°æ ¹× ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡

´ç´¢º´°ú ½ÉÇ÷°ü Áúȯ°ú °°Àº ¸¸¼º ÁúȯÀº ¼ö¼úÀû °³ÀÔÀÌ ÇÊ¿äÇÑ ÇÕº´ÁõÀ» ÀÏÀ¸Å°´Â °æ¿ì°¡ ¸¹À¸¸ç ½Ç½Ã°£ ½Å°æ ¸ð´ÏÅ͸µÀÌ Áß¿äÇÕ´Ï´Ù. Àüµµ¼º ½Å°æ ¸ð´ÏÅ͸µ ±â¼úÀº ¼ö¼ú ÈÄ Àå¾Ö¸¦ ÃÖ¼ÒÈ­Çϰí ȯÀÚÀÇ °á°ú¸¦ Çâ»ó½Ã۱â À§ÇØ ¼ö¼ú ¿öÅ© Ç÷ο쿡 ÅëÇյǴ °æ¿ì°¡ ¸¹½À´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä °æÁ¦±¹ Àα¸ÀÇ °í·ÉÈ­´Â ½Å°æ °ü·Ã ¼ö¼ú °Ç¼ö Áõ°¡¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç ½ÃÀå ¼ºÀåÀ» ´õ¿í °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ½Å°æ Áø´Ü µµ±¸¿Í °í±Þ ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀÇ À¶ÇÕµµÀÌ ºÐ¾ßÀÇ ±â¼ú Çõ½ÅÀ» ÃËÁøÇÕ´Ï´Ù.

Àåºñ ¹× ó¸®ÀÇ ³ôÀº ºñ¿ë

Àüµµ¼º ½Å°æ ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀº Á¤±³ÇÑ Çϵå¿þ¾î, µ¶ÀÚÀûÀÎ ¼ÒÇÁÆ®¿þ¾î, ¼÷·ÃµÈ ÀηÂÀÌ ÇÊ¿äÇϱ⠶§¹®¿¡ µµÀÔ ¹× À¯Áö¿¡ ºñ¿ëÀÌ µì´Ï´Ù. º´¿ø°ú ¼ö¼ú¼¾ÅÍ´Â ¿¹»êÀÇ Á¦¾à¿¡ Á÷¸éÇÏ´Â °æ¿ì°¡ ¸¹°í, ƯÈ÷ °³¹ß µµ»ó Áö¿ª¿¡¼­´Â ÀÌ·¯ÇÑ ±â¼úÀÇ µµÀÔÀÌ Á¦Çѵǰí ÀÖ½À´Ï´Ù. ¼Ò¸ðǰ, ±³Á¤, Á¤±âÀûÀÎ ¾÷±×·¹À̵忡 µå´Â ºñ¿ëµµ °æÁ¦Àû ºÎ´ã¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ º¸Çè »óȯÀÇ °úÁ¦³ª ½Å°æ ¸ð´ÏÅ͸µ ¼­ºñ½º¿¡ ´ëÇÑ º¸ÆíÀûÀÎ º¸ÇèÀÌ ¾ø´Â °ÍÀÌ ¼Ò±Ô¸ð ½Ã¼³ÀÌ ÀÌ·¯ÇÑ ½Ã½ºÅÛ¿¡ ÅõÀÚÇÒ ÀÇ¿åÀ» ±ð°í ÀÖ½À´Ï´Ù.

Ç¥ÁØÈ­µÈ »óȯ Á¤Ã¥ÀÇ ºÎÁ·

½Å°æ ¸ð´ÏÅ͸µÀÌ º¹ÀâÇÑ ¼ö¼ú¿¡¼­ Ç¥ÁØ Ä¡·á°¡ µÊ¿¡ µû¶ó ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü¿Í ¾÷°è °ü°èÀÚ´Â º¸´Ù ¸íÈ®ÇÑ Ã»±¸ ÄÚµå¿Í º¸Çè Àû¿ëÀ» ¿ä±¸Çϰí ÀÖ½À´Ï´Ù. ÀÌ °ÝÂ÷¸¦ ÅëÇØ ±â¾÷Àº ±ÔÁ¦ ±â°ü ¹× ÀÇ·á ´Üü¿Í Çù·ÂÇÏ¿© °¡Ä¡ ±â¹Ý °¡°Ý ¸ðµ¨À» ¼ö¸³ÇÒ ¼ö ÀÖ½À´Ï´Ù. ƯÈ÷ ½ÅÈï ½ÃÀåÀº µµÀÔÀÇ µ¿±âºÎ¿©°¡ µÇ´Â ü°èÀûÀÎ »óȯÁ¦µµÀÇ ±â°è°¡ ÀͰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ºñ¿ë È¿À²ÀûÀÎ ÈÞ´ë¿ë ´º·Î ¸ð´ÏÅ͸µ ÀåÄ¡ÀÇ °³¹ßÀº ±¸ÀÔÇϱ⠽¬¿î °¡°ÝÀÇ °¸À» ¸Þ¿ì°í ¾×¼¼½º¸¦ È®´ëÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

¸ð´ÏÅ͸µ ¼­ºñ½º ¾Æ¿ô¼Ò½Ì¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡

Ÿ»ç Á¦°ø¾÷ü´Â Àú·ÅÇÑ ºñ¿ëÀ¸·Î ¿ø°Ý ¸ð´ÏÅ͸µ ¼Ö·ç¼ÇÀ» Á¦°øÇÏ¿© ÀÚº» Áý¾àÀûÀÎ ¼³Ä¡ÀÇ Çʿ伺À» ÁÙÀÔ´Ï´Ù. ¾Æ¿ô¼Ò½ÌÀº È®À强°ú Àη ¹èÄ¡ À¯¿¬¼ºÀ» Çâ»ó½ÃŰÁö¸¸ µ¥ÀÌÅÍ ¾ÈÀü¼º, ¼­ºñ½º ½Å·Ú¼º, ÀÓ»ó Ã¥ÀÓ°ú °ü·ÃµÈ À§ÇèÀ» Á¦°øÇÕ´Ï´Ù. ¿ÜºÎ °ø±Þ¾÷ü¿¡ Å©°Ô ÀÇÁ¸ÇÏ´Â º´¿øÀº ÀϰüµÈ ǰÁú ±âÁØÀ» À¯ÁöÇÏ´Â µ¥ ¾î·Á¿òÀ» °ÞÀ» ¼ö ÀÖ½À´Ï´Ù. ÀÌ ÀüȯÀº ±âÁ¸ÀÇ ¼öÀÍ ¸ðµ¨À» ºØ±«½ÃÄÑ ¼­ºñ½º Á¦°ø¾÷ü¿Í Àåºñ Á¦Á¶¾÷ü °£ÀÇ °æÀïÀ» °ÝÈ­½Ãų ¼ö ÀÖ½À´Ï´Ù.

COVID-19ÀÇ ¿µÇâ :

°ø±Þ¸ÁÀÇ Áß´ÜÀº Áß¿äÇÑ ºÎǰÀÇ °¡¿ë¼º¿¡ ¿µÇâÀ» ÁÖ¾úÀ¸¸ç ¼³Ä¡ ¹× À¯Áöº¸¼ö ÀÏÁ¤À» ´ÊÃß¾ú½À´Ï´Ù. ±×·¯³ª ÀÌ À§±â´Â ¿ø°Ý ¸ð´ÏÅ͸µ°ú ¿ø°Ý ½Å°æÇÐÀÇ Á߿伺À» ºÎ°¢½ÃÄÑ ¹«¼±°ú Ŭ¶ó¿ìµå¸¦ ÅëÇÕÇÑ ½Å°æ ¸ð´ÏÅ͸µ Ç÷§ÆûÀÇ ±â¼ú Çõ½ÅÀ» Ã˱¸Çß½À´Ï´Ù. ÆÒ´ë¹Í ÀÌÈÄÀÇ È¸º¹À¸·Î ¼ö¼ú °Ç¼ö°¡ ȸº¹µÇ°í º´¿øÀº ¼ö¼ú Áß ¾ÈÀü¼ºÀ» ³ôÀ̰í ÇÕº´ÁõÀ» ÁÙÀÌ´Â ±â¼úÀ» ¿ì¼±ÇÏ°Ô µÇ¾î ½ÃÀå ±â¼¼°¡ ºÎȰÇß½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È ¸ð´ÏÅ͸µ ½Ã½ºÅÛ/À¯´Ö ºÐ¾ß°¡ ÃÖ´ëÈ­µÉ Àü¸Á

¸ð´ÏÅ͸µ ½Ã½ºÅÛ/À¯´Ö ºÐ¾ß´Â ¼ö¼ú Áß ½Å°æ»ý¸®ÇÐÀû Æò°¡¿¡¼­ Áß½ÉÀûÀÎ ¿ªÇÒÀ» Çϱ⠶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº ½Å°æ ±â´É¿¡ ´ëÇÑ ½Ç½Ã°£ Çǵå¹éÀ» Á¦°øÇÏ¿© ¿Ü°úÀǻ簡 º¹ÀâÇÑ ÀýÂ÷ Áß¿¡ Á¤º¸¸¦ ±â¹ÝÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ÷´Ü ÀåÄ¡´Â ÇöÀç AI ÁÖµµ ½ÅÈ£ ÇØ¼®, ´ÙÁß ¸ðµå ÅëÇÕ ¹× ¹«¼± ¿¬°áÀ» ÅëÇÕÇÏ¿© Á¤È®¼º°ú »ç¿ë ÆíÀǼºÀ» Çâ»ó½Ãŵ´Ï´Ù. ½Å°æ ¿Ü°ú, Á¤Çü¿Ü°ú, ½ÉÀåÇ÷°ü ¿Ü°úÀÇ °¢ ºÐ¾ß¿¡¼­ ³Î¸® ä¿ëµÇ°í Àֱ⠶§¹®¿¡ ±× ¹ü¿ë¼ºÀÌ µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È ôÃß ¿Ü°ú ºÐ¾ßÀÇ °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»ó

¿¹Ãø ±â°£ µ¿¾È, ôÃß º¯Çü ±³Á¤, Á¾¾ç ÀýÁ¦, Ãß°£ÆÇ º¯¼º ¼ö¼ú Áõ°¡´Â ôÃß ¼ö¼ú ºÐ¾ß°¡ °¡Àå ³ôÀº ¼ºÀå·üÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Àüµµ¼º ½Å°æ ¸ð´ÏÅ͸µÀº ÀÌ·¯ÇÑ ¼ö¼ú Áß¿¡ ¿îµ¿ °æ·Î¿Í °¨°¢ °æ·Î¸¦ À¯ÁöÇÏ°í ¸¶ºñ¿Í ½Å°æ ¼Õ»óÀÇ À§ÇèÀ» ÁÙÀÌ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Àü±Ø ¼³°è, ½ÅÈ£ Ãæ½Çµµ ¹× ½Ç½Ã°£ ºÐ¼®ÀÇ ±â¼ú Çõ½ÅÀ¸·Î ½Å°æ ¸ð´ÏÅ͸µÀº ôÃß ¼ö¼ú½Ç¿¡ ÇʼöÀûÀÔ´Ï´Ù. ôÃß Ä¡·á¿¡¼­ ½Å°æ ¸ð´ÏÅÍÀÇ ÀÌÁ¡¿¡ ´ëÇØ ¿Ü°úÀÇ»ç¿Í ȯÀÚµé »çÀÌ¿¡¼­ ÀνÄÀÌ Áõ°¡ÇÏ´Â °Íµµ ¼ºÀå °¡¼Ó¿¡ ±â¿©ÇÕ´Ï´Ù.

ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇÏ´Â Áö¿ª

¿¹Ãø ±â°£ µ¿¾È ºÏ¹Ì´Â °ß°íÇÑ °Ç°­ °ü¸® ÀÎÇÁ¶ó¿Í ¼ö¼ú °Ç¼ö°¡ ¸¹±â ¶§¹®¿¡ ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ Áö¿ªÀº ¼±ÁøÀûÀÎ ½Å°æ ¸ð´ÏÅ͸µ ±â¼úÀÇ Á¶±â µµÀÔ°ú ´ë±â¾÷ Á¦Á¶ ¾÷üÀÇ Á¸Àç°¨ÀÇ °­µµ°¡ ÀåÁ¡ÀÌ µÇ°í ÀÖ½À´Ï´Ù. È£ÀÇÀûÀÎ »óȯ Á¤Ã¥°ú È®¸³µÈ ÀÓ»ó ÁöħÀÌ ´õ¿í º¸±ÞÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹°ú ij³ª´ÙÀÇ Çмú±â°ü°ú ¿¬±¸¼¾ÅÍ´Â ±â¼úÀÇ Áøº¸¿Í ÀÓ»ó °ËÁõ¿¡ Àû±ØÀûÀ¸·Î ±â¿©Çϰí ÀÖ½À´Ï´Ù.

°¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³»´Â Áö¿ª :

¿¹Ãø ±â°£ µ¿¾È ÀÇ·á Á¢±Ù¼º È®´ë, ¿Ü°ú ¼ö¼ú Áõ°¡, ÀÇ·á ±â¼ú ÅõÀÚ Áõ°¡·Î ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Áß±¹, Àεµ, Çѱ¹°ú °°Àº ±¹°¡µéÀº ¼ö¼ú ÀÎÇÁ¶ó¸¦ ±Þ¼ÓÈ÷ Çö´ëÈ­Çϰí ÀÖÀ¸¸ç, ½Å°æ ¸ð´ÏÅ͸µ äÅÃÀ» À§ÇÑ ºñ¿ÁÇÑ Åä¾çÀ» »ý»êÇϰí ÀÖ½À´Ï´Ù. ½Å°æ Äɾî¿Í ¼ö¼úÀÇ ¾ÈÀü¼º Çâ»óÀ» ¸ñÇ¥·Î ÇÏ´Â Á¤ºÎÀÇ ´ëó°¡ ½ÃÀå È®´ë¸¦ ´õ¿í µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ÇöÁö Á¦Á¶¾÷ü´Â Áö¿ªÀÇ ¿ä±¸¿¡ ¸Â´Â ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ¸·Î ÀÌ ºÐ¾ß¿¡ ÁøÃâÇØ °æÀï°ú ±â¼ú Çõ½ÅÀ» °ÝÈ­½Ã۰í ÀÖ½À´Ï´Ù.

¹«·á ÁÖ¹®À» ¹Þ¾Æ¼­ ¸¸µå´Â ¼­ºñ½º :

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´Àº ´ÙÀ½ ¹«·á ¸ÂÃã¼³Á¤ ¿É¼Ç Áß Çϳª¸¦ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Ãß°¡ ½ÃÀå ±â¾÷ÀÇ Á¾ÇÕÀû ÇÁ·ÎÆÄÀϸµ(3°³»ç±îÁö)
    • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®(3°³»ç±îÁö)
  • Áö¿ª ¼¼ºÐÈ­
    • °í°´ÀÇ °ü½É¿¡ ÀÀÇÑ ÁÖ¿ä±¹ ½ÃÀå Ã߰衤¿¹Ãø¡¤CAGR(ÁÖ : Ÿ´ç¼º È®Àο¡ µû¸§)
  • °æÀï º¥Ä¡¸¶Å·
    • Á¦Ç° Æ÷Æ®Æú¸®¿À, Áö¸®Àû Á¸Àç, Àü·«Àû Á¦ÈÞ¿¡ ±â¹ÝÇÑ ÁÖ¿ä ±â¾÷ º¥Ä¡¸¶Å·

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­¹®

  • °³¿ä
  • ÀÌÇØ°ü°èÀÚ
  • Á¶»ç ¹üÀ§
  • Á¶»ç ¹æ¹ý
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • µ¥ÀÌÅÍ ºÐ¼®
    • µ¥ÀÌÅÍ °ËÁõ
    • Á¶»ç Á¢±Ù
  • Á¶»ç ÀÚ·á
    • 1Â÷ Á¶»ç ÀÚ·á
    • 2Â÷ Á¶»ç Á¤º¸¿ø
    • ÀüÁ¦Á¶°Ç

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • À§Çù
  • Á¦Ç°ºÐ¼®
  • ¿ëµµ ºÐ¼®
  • ÃÖÁ¾ »ç¿ëÀÚ ºÐ¼®
  • ½ÅÈï ½ÃÀå
  • COVID-19ÀÇ ¿µÇâ

Á¦4Àå Porter's Five Forces ºÐ¼®

  • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
  • ±¸¸ÅÀÚÀÇ Çù»ó·Â
  • ´ëüǰÀÇ À§Çù
  • ½Å±Ô Âü°¡¾÷üÀÇ À§Çù
  • °æÀï ±â¾÷ °£ °æÀï °ü°è

Á¦5Àå ¼¼°èÀÇ Àüµµ¼º ½Å°æ ¸ð´ÏÅ͸µ ½ÃÀå : Á¦Ç° À¯Çüº°

  • Àü±Ø
    • ÇÇÇÏ ¹Ù´Ã Àü±Ø
    • Ç¥¸é Àü±Ø
    • ³úÇÇÁúÀüµµµµ°Ë»ç(ECoG) Àü±Ø
  • ¸ð´ÏÅ͸µ ½Ã½ºÅÛ/ÀåÄ¡
    • ³úÆÄ °Ë»ç(EEG) Àåºñ
    • ±ÙÀüµµ °Ë»ç(EMG) Àåºñ
    • À¯¹ß ÀüÀ§(EP) ½Ã½ºÅÛ
      • ü¼º °¨°¢ À¯¹ß ÀüÀ§(SSEP)
      • ¿îµ¿ À¯¹ß ÀüÀ§(MEP)
      • ³ú°£ û°¢ À¯¹ß ÀüÀ§(BAEP)
      • ½Ã°¢ À¯¹ß ÀüÀ§(VEP)
    • ´ÙÁß ¸ðµå ½Ã½ºÅÛ
  • ¾×¼¼¼­¸® ¹× ¼Ò¸ðǰ
    • ÄÉÀÌºí ¹× ¸®µå
    • Àüµµ¼º Á© ¹× ÆäÀ̽ºÆ®
    • Àڱرâ

Á¦6Àå ¼¼°èÀÇ Àüµµ¼º ½Å°æ ¸ð´ÏÅ͸µ ½ÃÀå : ¼Ò½º À¯Çüº°

  • ³»ºÎ ¸ð´ÏÅ͸µ
  • ¿ÜºÎ ¸ð´ÏÅ͸µ

Á¦7Àå ¼¼°èÀÇ Àüµµ¼º ½Å°æ ¸ð´ÏÅ͸µ ½ÃÀå : ¿ëµµº°

  • ôÃß ¼ö¼ú
    • °¨¾Ð ¼ö¼ú
    • ôÃß À¯ÇÕ¼ú
    • ôÃß Ãø¸¸Áõ ±³Á¤¼ú
  • ½Å°æ¿Ü°ú ¼ö¼ú
    • ³úÁ¾¾ç ÀýÁ¦¼ú
    • µ¿¸Æ·ù Ŭ¸®Çμú
    • ±â´ÉÀû ½Å°æ¿Ü°ú ¼ö¼ú(DBS)
  • Ç÷°ü ¼ö¼ú
  • À̺ñÀÎÈİú ¼ö¼ú
  • ±âŸ ¿ëµµ

Á¦8Àå ¼¼°èÀÇ Àüµµ¼º ½Å°æ ¸ð´ÏÅ͸µ ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • º´¿ø
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • Àü¹® ½Å°æÇÐ ¹× ½Å°æ¿Ü°ú ¼¾ÅÍ
  • ±âŸ ÃÖÁ¾ »ç¿ëÀÚ

Á¦9Àå ¼¼°èÀÇ Àüµµ¼º ½Å°æ ¸ð´ÏÅ͸µ ½ÃÀå : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ´ºÁú·£µå
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ³²¹Ì
    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • Ä¥·¹
    • ±âŸ ³²¹Ì
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • īŸ¸£
    • ³²¾ÆÇÁ¸®Ä«
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå ÁÖ¿ä ¹ßÀü

  • °è¾à, ÆÄÆ®³Ê½Ê, Çù¾÷, ÇÕÀÛÅõÀÚ
  • Àμö¿Í ÇÕº´
  • ½ÅÁ¦Ç° ¹ß¸Å
  • »ç¾÷ È®´ë
  • ±âŸ ÁÖ¿ä Àü·«

Á¦11Àå ±â¾÷ ÇÁ·ÎÆÄÀϸµ

  • Zimmer Biomet Holdings, Inc.
  • SpecialtyCare, Inc.
  • RHONEDERM GmbH
  • NuVasive, Inc.
  • Nihon Kohden Corporation
  • NeuroWave Systems Inc.
  • Neurosign Medical
  • Natus Medical Incorporated
  • Medtronic plc
  • Magstim Company Limited
  • LivaNova PLC
  • International Medical Systems Ltd.
  • Inomed Medizintechnik GmbH
  • GE HealthCare
  • Erbe Elektromedizin GmbH
  • Dr. Langer Medical GmbH
  • Computronics Healthcare
  • Cadwell Industries, Inc.
  • Bionen Co., Ltd.
  • AD-Tech Medical Instrument Corporation
KTH

According to Stratistics MRC, the Global Conductive Neuromonitoring Market is accounted for $374.8 million in 2025 and is expected to reach $605.8 million by 2032 growing at a CAGR of 7.1% during the forecast period. Conductive neuromonitoring is the real-time assessment of neural pathway integrity using electrophysiological techniques that measure electrical conduction across the central and peripheral nervous systems. Commonly employed during surgical procedures, it utilizes modalities such as somatosensory evoked potentials (SSEPs), motor evoked potentials (MEPs), and electromyography (EMG) to detect potential neural compromise. This approach enables clinicians to identify and prevent intraoperative neurological injury by providing continuous feedback on functional status, thereby enhancing patient safety and surgical outcomes.

Market Dynamics:

Driver:

Increasing prevalence of neurological and chronic disorders

Chronic disorders like diabetes and cardiovascular diseases often lead to complications requiring surgical interventions, where real-time nerve monitoring becomes critical. Conductive neuromonitoring technologies are increasingly integrated into surgical workflows to minimize postoperative deficits and enhance patient outcomes. Moreover, aging populations across major economies are contributing to a higher volume of neuro-related procedures, further accelerating market growth. The convergence of neurodiagnostic tools with advanced monitoring systems is also fostering innovation in this space.

Restraint:

High cost of equipment and procedures

Conductive neuromonitoring systems involve sophisticated hardware, proprietary software, and skilled personnel, making them expensive to deploy and maintain. Hospitals and surgical centers often face budget constraints, limiting the adoption of these technologies, especially in developing regions. The cost of consumables, calibration, and periodic upgrades adds to the financial burden. Additionally, reimbursement challenges and lack of universal coverage for neuromonitoring services discourage smaller facilities from investing in these systems.

Opportunity:

Lack of standardized reimbursement policies

As neuromonitoring becomes a standard of care in complex surgeries, healthcare providers and industry players are pushing for clearer billing codes and insurance coverage. This gap allows companies to collaborate with regulatory bodies and medical associations to establish value-based pricing models. Emerging markets, in particular, are ripe for structured reimbursement systems that can incentivize adoption. Furthermore, the development of cost-effective, portable neuromonitoring units may help bridge affordability gaps and expand access.

Threat:

Growing demand for outsourced monitoring services

Third-party providers offer remote monitoring solutions at lower costs, reducing the need for capital-intensive installations. While outsourcing improves scalability and staffing flexibility, it also introduces risks related to data security, service reliability, and clinical accountability. Hospitals relying heavily on external vendors may face challenges in maintaining consistent quality standards. This shift could potentially disrupt traditional revenue models and intensify competition among service providers and device manufacturers.

Covid-19 Impact:

Supply chain interruptions affected the availability of critical components, delaying installations and maintenance schedules. However, the crisis also underscored the importance of remote monitoring and tele-neurology, prompting innovation in wireless and cloud-integrated neuromonitoring platforms. Post-pandemic recovery has seen a rebound in surgical volumes, with hospitals prioritizing technologies that enhance intraoperative safety and reduce complications, thereby revitalizing market momentum.

The monitoring systems/units segment is expected to be the largest during the forecast period

The monitoring systems/units segment is expected to account for the largest market share during the forecast period due to its central role in intraoperative neurophysiological assessments. These systems offer real-time feedback on nerve function, enabling surgeons to make informed decisions during complex procedures. Advanced units now incorporate AI-driven signal interpretation, multi-modality integration, and wireless connectivity, enhancing precision and usability. Their widespread adoption across neurosurgery, orthopedic, and cardiovascular disciplines underscores their versatility.

The spinal surgery segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the spinal surgery segment is predicted to witness the highest growth rate driven by the increasing number of spinal deformity corrections, tumor resections, and degenerative disc interventions. Conductive neuromonitoring plays a vital role in preserving motor and sensory pathways during these procedures, reducing the risk of paralysis or nerve damage. Innovations in electrode design, signal fidelity, and real-time analytics are making neuromonitoring indispensable in spinal operating rooms. The rising awareness among surgeons and patients about the benefits of neuromonitoring in spinal care is also contributing to its accelerated growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share attributed to its robust healthcare infrastructure and high surgical volumes. The region benefits from early adoption of advanced neuromonitoring technologies and strong presence of leading device manufacturers. Favorable reimbursement policies and well-established clinical guidelines further encourage widespread use. Academic institutions and research centers in the U.S. and Canada are actively contributing to technological advancements and clinical validation.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR propelled by expanding healthcare access, rising surgical procedures, and increasing investments in medical technology. Countries like China, India, and South Korea are rapidly modernizing their surgical infrastructure, creating fertile ground for neuromonitoring adoption. Government initiatives aimed at improving neurological care and surgical safety are further driving market expansion. Local manufacturers are entering the space with cost-effective solutions tailored to regional needs, intensifying competition and innovation.

Key players in the market

Some of the key players in Conductive Neuromonitoring Market include Zimmer Biomet Holdings, Inc., SpecialtyCare, Inc., RHONEDERM GmbH, NuVasive, Inc., Nihon Kohden Corporation, NeuroWave Systems Inc., Neurosign Medical, Natus Medical Incorporated, Medtronic plc, Magstim Company Limited, LivaNova PLC, International Medical Systems Ltd., Inomed Medizintechnik GmbH, GE HealthCare, Erbe Elektromedizin GmbH, Dr. Langer Medical GmbH, Computronics Healthcare, Cadwell Industries, Inc., Bionen Co., Ltd., and AD-Tech Medical Instrument Corporation.

Key Developments:

In July 2025, Zimmer Biomet announced a definitive agreement to acquire Monogram Technologies to expand its robotics suite with semi- and fully-autonomous solutions (deal value reported ~$177M). The release frames the acquisition as adding autonomy to Zimmer's robotics roadmap and accelerating commercialization of semi/fully autonomous joint-replacement tech.

In June 2025, LivaNova announced it had initiated a CMS reconsideration process for national Medicare coverage of VNS Therapy and later issued Q2 2025 results / guidance updates. The announcements focus on reimbursement strategy for VNS and financial performance for 2025.

In May 2025, Natus Medical Incorporated announced the launch of BrainWatch(TM), a point-of-care EEG solution designed for critical-care settings. The release explains the product positioning (POC EEG for ICU/ED), key features and Natus's commercialization plans for 2025.

Product Types Covered:

  • Electrodes
  • Monitoring Systems/Units
  • Accessories & Disposables

Source Types Covered:

  • Insourced Monitoring
  • Outsourced Monitori

Applications Covered:

  • Spinal Surgery
  • Neurosurgery
  • Vascular Surgery
  • ENT Surgery
  • Other Applications

End Users Covered:

  • Hospitals
  • Ambulatory Surgical Centers (ASCs)
  • Specialty Neurology & Neurosurgery Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Conductive Neuromonitoring Market, By Product Type

  • 5.1 Introduction
  • 5.2 Electrodes
    • 5.2.1 Subdermal Needle Electrodes
    • 5.2.2 Surface Electrodes
    • 5.2.3 Electrocorticography (ECoG) Electrodes
  • 5.3 Monitoring Systems/Units
    • 5.3.1 Electroencephalography (EEG) Machines
    • 5.3.2 Electromyography (EMG) Machines
    • 5.3.3 Evoked Potential (EP) Systems
      • 5.3.3.1 Somatosensory Evoked Potentials (SSEPs)
      • 5.3.3.2 Motor Evoked Potentials (MEPs)
      • 5.3.3.3 Brainstem Auditory Evoked Potentials (BAEPs)
      • 5.3.3.4 Visual Evoked Potentials (VEPs)
    • 5.3.4 Multimodality Systems
  • 5.4 Accessories & Disposables
    • 5.4.1 Cables & Leads
    • 5.4.2 Conductive Gels and Pastes
    • 5.4.3 Stimulators

6 Global Conductive Neuromonitoring Market, By Source Type

  • 6.1 Introduction
  • 6.2 Insourced Monitoring
  • 6.3 Outsourced Monitoring

7 Global Conductive Neuromonitoring Market, By Application

  • 7.1 Introduction
  • 7.2 Spinal Surgery
    • 7.2.1 Decompression Surgery
    • 7.2.2 Spinal Fusion
    • 7.2.3 Scoliosis Correction
  • 7.3 Neurosurgery
    • 7.3.1 Brain Tumor Resection
    • 7.3.2 Aneurysm Clipping
    • 7.3.3 Functional Neurosurgery (DBS)
  • 7.4 Vascular Surgery
  • 7.5 ENT Surgery
  • 7.6 Other Applications

8 Global Conductive Neuromonitoring Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Ambulatory Surgical Centers (ASCs)
  • 8.4 Specialty Neurology & Neurosurgery Centers
  • 8.5 Other End Users

9 Global Conductive Neuromonitoring Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Zimmer Biomet Holdings, Inc.
  • 11.2 SpecialtyCare, Inc.
  • 11.3 RHONEDERM GmbH
  • 11.4 NuVasive, Inc.
  • 11.5 Nihon Kohden Corporation
  • 11.6 NeuroWave Systems Inc.
  • 11.7 Neurosign Medical
  • 11.8 Natus Medical Incorporated
  • 11.9 Medtronic plc
  • 11.10 Magstim Company Limited
  • 11.11 LivaNova PLC
  • 11.12 International Medical Systems Ltd.
  • 11.13 Inomed Medizintechnik GmbH
  • 11.14 GE HealthCare
  • 11.15 Erbe Elektromedizin GmbH
  • 11.16 Dr. Langer Medical GmbH
  • 11.17 Computronics Healthcare
  • 11.18 Cadwell Industries, Inc.
  • 11.19 Bionen Co., Ltd.
  • 11.20 AD-Tech Medical Instrument Corporation
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦